Razavi H. The cost-effectiveness of hepatitis C virus elimination in low- and middle-income countries. J Viral Hepat. 2021 Feb;28(2):445. doi: 10.1111/jvh.13442. Epub 2020 Dec 1. PMID: 33205589.
Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, AlMasri N, Razavi-Shearer D, Razavi H, Schmelzer J, Alfaleh FZ. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia. J Infect Public Health. 2020 Nov;13(11):1715-1723. doi: 10.1016/j.jiph.2020.09.004. Epub 2020 Sep 26. PMID: 32988769. Summary Background […]
Örmeci N, Malhan S, Balık İ, Ergör G, Razavi H, Robbins S. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatol Int. 2017 Nov;11(6):509-516. doi: 10.1007/s12072-017-9820-3. Epub 2017 Oct 12. PMID: 29027109. Summary Background Hepatitis C virus (HCV) infection is a significant health problem. The aim of […]
Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol Ther. 2015 Sep;42(6):696-706. doi: 10.1111/apt.13316. Epub 2015 Jul 22. PMID: 26202593; PMCID: PMC5034818. Summary Background The prevalence of hepatitis […]
Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS One. 2015 Jun 24;10(6):e0125214. doi: 10.1371/journal.pone.0125214. PMID: 26107467; PMCID: PMC4480969. Summary Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland […]
Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014 Aug;29 Suppl 1:1-9. doi: 10.1111/jgh.12677. PMID: 25055928. Summary Background and aim Chronic hepatitis C virus (HCV) infection […]
Mennini FS, Marcellusi A, Andreoni M, Gasbarrini A, Salomone S, Craxì A. Health policy model: long-term predictive results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res. 2014 Jun 19;6:303-10. doi: 10.2147/CEOR.S62092. PMID: 24971024; PMCID: PMC4069043. Summary Background At present, there are no specific nationwide epidemiological studies representing the whole […]
Vandijck D, Moreno C, Stärkel P, Van Damme P, Van Vlierberghe H, Hindman SJ, Razavi H, Laleman W. Current and future health and economic impact of hepatitis C in Belgium. Acta Gastroenterol Belg. 2014 Jun;77(2):285-90. PMID: 25090835. Summary Background and Study Aims Chronic hepatitis C virus (HCV) infection is a serious global health problem affecting […]
Vandijck D, Stärkel P. Innovative strategies for hepatitis C in Belgium integrating treatment efficacy, public disease burden, and healthcare costs. Acta Gastroenterol Belg. 2014 Jun;77(2):274-6. PMID: 25090832. Countries: Belgium
Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014 May;28(5):243-50. doi: 10.1155/2014/317623. PMID: 24839620; PMCID: PMC4049256. Summary Background Chronic infection with hepatitis C virus (HCV) is a […]